(Q38051546)

27 August 2017

title

Will T-cell therapy for cancer ever be a standard of care? (English)

1 reference

27 August 2017

M K Brenner

1

1 reference

27 August 2017

publication date

12 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

19

1 reference

27 August 2017

issue

12

1 reference

27 August 2017

page(s)

818-821

1 reference

https://scigraph.springernature.com/pub.10.1038/cgt.2012.74

27 August 2017

exact match

0 references

cites work

PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine.

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Advances in graft-versus-host disease biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Getting personal with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Hematopoietic stem cell engineering at a crossroads

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

CARs on track in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

The promise and potential pitfalls of chimeric antigen receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

An inducible caspase 9 safety switch for T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

Prospects and limitations of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCGT.2012.74

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CGT.2012.74

1 reference

27 August 2017

1 reference